Sarepta Therapeutics (NASDAQ:SRPT) Given New $165.00 Price Target at Cantor Fitzgerald

Sarepta Therapeutics (NASDAQ:SRPT – Get Rating) had its price objective dropped by equities research analysts at Cantor Fitzgerald from $178.00 to $165.00 in a research note issued on Friday, The Fly reports. Cantor Fitzgerald’s price objective would indicate a potential upside of 34.49% from the stock’s current price.

Several other research analysts have also weighed in on the stock. Needham & Company LLC cut their price objective on shares of Sarepta Therapeutics from $200.00 to $160.00 and set a “buy” rating on the stock in a report on Friday. UBS Group upgraded shares of Sarepta Therapeutics from a “neutral” rating to a “buy” rating and increased their price objective for the stock from $100.00 to $158.00 in a report on Friday, December 16th. Royal Bank of Canada increased their price objective on shares of Sarepta Therapeutics from $195.00 to $226.00 and gave the stock an “outperform” rating in a report on Wednesday, March 1st. Credit Suisse Group dropped their target price on shares of Sarepta Therapeutics from $144.00 to $139.00 and set a “neutral” rating for the company in a research report on Friday. Finally, Robert W. Baird increased their target price on shares of Sarepta Therapeutics from $152.00 to $202.00 and gave the stock an “outperform” rating in a research report on Wednesday, March 1st. Two equities research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $165.88.

Sarepta Therapeutics Stock Down 18.0 %

NASDAQ:SRPT opened at $122.69 on Friday. The company has a debt-to-equity ratio of 4.01, a quick ratio of 3.80 and a current ratio of 4.13. The company’s 50-day moving average is $129.49 and its two-hundred day moving average is $120.17. Sarepta Therapeutics has a 12-month low of $61.28 and a 12-month high of $159.84.

Sarepta Therapeutics (NASDAQ:SRPT – Get Rating) last announced its quarterly earnings data on Tuesday, February 28th. The biotechnology company reported ($1.24) earnings per share for the quarter, topping the consensus estimate of ($1.28) by $0.04. The business had revenue of $258.43 million for the quarter, compared to analyst estimates of $250.51 million. Sarepta Therapeutics had a negative net margin of 75.40% and a negative return on equity of 117.29%. The company’s revenue was up 28.3% on a year-over-year basis. During the same period in the prior year, the firm posted ($1.42) EPS. Research analysts expect that Sarepta Therapeutics will post -4.14 EPS for the current fiscal year.

Hedge Funds Weigh In On Sarepta Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in the business. FourThought Financial LLC lifted its stake in Sarepta Therapeutics by 43.5% during the third quarter. FourThought Financial LLC now owns 297 shares of the biotechnology company’s stock worth $33,000 after purchasing an additional 90 shares during the last quarter. AQR Capital Management LLC lifted its stake in Sarepta Therapeutics by 3.5% during the fourth quarter. AQR Capital Management LLC now owns 2,826 shares of the biotechnology company’s stock worth $366,000 after purchasing an additional 95 shares during the last quarter. Exchange Traded Concepts LLC lifted its stake in Sarepta Therapeutics by 16.5% during the fourth quarter. Exchange Traded Concepts LLC now owns 685 shares of the biotechnology company’s stock worth $89,000 after purchasing an additional 97 shares during the last quarter. Utah Retirement Systems lifted its stake in Sarepta Therapeutics by 0.7% during the third quarter. Utah Retirement Systems now owns 14,971 shares of the biotechnology company’s stock worth $1,654,000 after purchasing an additional 100 shares during the last quarter. Finally, Neuberger Berman Group LLC lifted its stake in Sarepta Therapeutics by 2.5% during the third quarter. Neuberger Berman Group LLC now owns 4,250 shares of the biotechnology company’s stock worth $470,000 after purchasing an additional 105 shares during the last quarter. 87.31% of the stock is currently owned by hedge funds and other institutional investors.

About Sarepta Therapeutics

(Get Rating)

Sarepta Therapeutics, Inc is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.